



Gubra strengthens Board of Directors

Gubra, a leader in preclinical services within metabolic and fibrotic diseases and with a strong pipeline of novel discovery projects, today announced the election of Monika Lessl and Astrid Haug as new independent members of the Board of Directors as of November 1st, 2023.

Monika Lessl, a German citizen, is an internationally experienced pharma executive with more than 15 years R&D leadership experience from Bayer AG (Germany). Monika is currently Executive Director of Bayer Foundation, and Senior Vice President; Head of Corporate R&D and Social Innovation Bayer AG. She holds a PhD in Biochemistry from the Max Planck Institute for Molecular Genetics in Berlin. In her former role as Head of Innovation Strategy she developed and led Bayer's Innovation Agenda to strengthen Bayer's Innovation capabilities and foster new business models. As Head of External Innovation Therapeutics at Bayer's pharmaceutical division she was responsible for creating the external innovation strategy and leading global partnering activities. Besides her executive role, she is a Board member of the Futurium, Berlin's museum of the future, and acts as a jury member of the European Innovation Council and the German Ministry of Science and Education.

Astrid Haug, a Danish citizen, is an independent consultant in Astrid Haug ApS bureau, consulting private companies, organisations, start-ups and funds on digital strategy, social media, innovation, and green impact communication. She is the author of six books and recognised as an expert on radio and television debates and other media covering these topics. Astrid holds a cand. mag. in Media Sciences and is Member of Faculty at CBS/Børsen Executive Board education and member of the Digital Council at the Danish Academy of Technical Sciences. Besides that, she acts as board member in UNICEF Denmark (Chair), Symbion A/S, Nørrebro Teater and in two start-ups; Re-Zip Aps and Veras ApS (Veras vintage).

Jacob Jelsing, Chair of Gubra, said: "I am very pleased to welcome Monika and Astrid, each bringing strong complementary competencies and experiences to the board of directors of Gubra. With Monika's knowhow and strong focus on driving organizations, while promoting innovation and sustainability through strategic initiatives and partnerships, she is a perfect fit for Gubras planned international expansion. Similarly, Astrid will be playing an important role on our continued focus on digital innovation, branding, and marketing, as well as our strong ESG commitment."

Astrid Haug said:

"Gubra is a remarkable company demonstrating that a highly innovative business with a long history of profitable growth goes hand in hand with a strong ESG commitment. I am delighted to be part of the board and to contribute to unfold Gubra's further potential."

Monika Lessl said:

"With Gubra's strong focus on partnerships and international expansion, as recently demonstrated with the new Gubra Inc. entity in US, I look forward to contributing as a board member to take both the discovery pipeline and the contract research business to the next level."



After the Extraordinary General Meeting the board of directors now consists of six members:

- Jacob Jelsing, Chair
- Alexander Martensen-Larsen, Vice Chair, independent board member
- Henriette Dræbye Rosenquist, independent board member
- Arndt Schottelius, independent board member
- Monika Lessl, independent board member
- Astrid Haug, independent board member

Contacts at Gubra

Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586

Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Gubra

Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen in 2023, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

Image Attachments

[Monika Lessl Picture](#)

[Astrid Haug Picture](#)

Attachments

[Gubra strengthens Board of Directors](#)